NYU surgeon transplants an engineered pig kidney into the outside of a brain-dead patient (Joe Carrotta/NYU Langone Health)

No, sci­en­tists are not any clos­er to pig-to-hu­man trans­plants than they were last week

Steve Holtz­man was awok­en by a 1 a.m. call from a doc­tor at Duke Uni­ver­si­ty ask­ing if he could put some pigs on a plane and fly them from Ohio to North Car­oli­na that day. A mo­tor­cy­clist had got­ten in­to a hor­rif­ic crash, the doc­tor ex­plained. He be­lieved the pigs’ liv­ers, su­tured on­to the pa­tient’s skin like an ex­ter­nal fil­ter, might be able to tide the young man over un­til a donor liv­er be­came avail­able.

Holtz­man was the pres­i­dent of DNX, one of the first com­pa­nies to try to use biotech­nol­o­gy to make pig-to-hu­man trans­plants pos­si­ble. He had amassed a pathogen-free porcine fa­cil­i­ty for their work and so oblig­ed, putting some un­lucky hogs on an Ohio State Uni­ver­si­ty plane to Duke, where one of ul­ti­mate­ly four pa­tients treat­ed with the pro­ce­dure sur­vived to re­ceive a new hu­man liv­er. The re­sults were pub­lished in the New Eng­land Jour­nal of Med­i­cine in 1994.

Which is why Holtz­man was shocked and a lit­tle bit con­fused when he read re­ports this week that doc­tors at NYU had con­duct­ed a “ground­break­ing” pro­ce­dure by, with the fam­i­ly’s con­sent, tak­ing a pig kid­ney and su­tur­ing it to the leg of a brain-dead pa­tient for 54 hours.

It was some­thing sci­en­tists could’ve done for years, he said. And it didn’t get them clos­er to ac­tu­al­ly mak­ing an­i­mal-to-hu­man trans­plants pos­si­ble, or ad­dress­ing the field’s main goal: solv­ing a na­tion­al or­gan short­age that kills 20 Amer­i­cans per day.

Steve Holtz­man

“It is hype and bull­shit,” said Holtz­man, who is now the chair­man of a Chi­nese com­pa­ny work­ing on xeno­trans­plan­ta­tion. “It be­longs in the Na­tion­al En­quir­er.”

Oth­er ex­perts with­in the small and large­ly in­su­lar world of xeno­trans­plan­ta­tion — the tech­ni­cal term for an­i­mal-to-hu­man trans­plants — were more sub­dued. Pig kid­neys, they said, are more dif­fi­cult to en­graft in a hu­man than pig liv­ers. And they not­ed Robert Mont­gomery, the NYU sur­geon, and Unit­ed Ther­a­peu­tics, the com­pa­ny that sup­plied the ge­net­i­cal­ly mod­i­fied pig, were not the first ones to con­ceive of this type of pro­ce­dure.

Yet while many were glad to see xeno­trans­plan­ta­tion get main­stream at­ten­tion af­ter two decades in which much of the field worked in ob­scu­ri­ty, they strug­gled to see the ex­act re­search ques­tion the ex­per­i­ment an­swered or the sci­en­tif­ic knowl­edge gained.

Al­though DNX and oth­er 90s-era xeno­trans­plant com­pa­nies flamed out for a va­ri­ety of rea­sons, sci­en­tists have known since the ear­ly 2000s that a sin­gle ge­net­ic ed­it should al­low or­gans to sur­vive for days, if not months, in a pa­tient. The re­al ques­tion is get­ting pig or­gans to con­sis­tent­ly sur­vive long-term, a much high­er im­muno­log­ic hur­dle.

The best some could say was that the work con­firmed what they al­ready knew.

Megan Sykes

“The re­sult doesn’t con­tain any sur­pris­es for those of us in this trans­plant field,” said Megan Sykes, di­rec­tor of Co­lum­bia’s cen­ter for trans­la­tion­al im­munol­o­gy. In that sense, it was a “good first step.”

For those who missed it, on Tues­day night, USA To­day pub­lished an in­tri­cate fea­ture de­tail­ing how, in late Sep­tem­ber, with $3.2 mil­lion in fund­ing from Unit­ed Ther­a­peu­tics, Mont­gomery con­nect­ed a mod­i­fied pig kid­ney to the leg of a 66-year-old woman who had re­cent­ly been de­clared brain-dead.

The pa­tient’s fam­i­ly was ap­proached, with the ad­vice of bioethi­cists, be­cause they want­ed to do­nate her or­gans but they weren’t fit for trans­plant. It of­fered an­oth­er way to help ad­vance med­i­cine that could one day save lives, they ex­plained.

The kid­ney be­gan fil­ter­ing her blood in­to urine with­in min­utes and stayed pink and func­tion­al for just over 2 days. Cru­cial­ly, Mont­gomery said, there was no ev­i­dence of in­stant re­jec­tion.

“As you all know, this is re­al­ly im­por­tant,” he said af­ter­wards. “This is go­ing to take us to the next step, which is hav­ing or­gans avail­able to every­one who needs them at any time.”

The sto­ry was soon picked up by The New York Times, Econ­o­mist, BBC and Al Jazeera, along with AP and Reuters re­ports that were reprint­ed wide­ly. The pro­ce­dure, the Times said, was “a sci­en­tif­ic break­through that one day may yield a vast new sup­ply of or­gans for se­vere­ly ill pa­tients.”

The xeno­trans­plan­ta­tion field has in­deed been inch­ing to­ward that goal for two decades, slow­ly build­ing it­self up af­ter falling apart in the 1990s, when com­pa­nies such as DNX and No­var­tis poured bil­lions in­to en­gi­neer­ing an­i­mals in­to donors. That decade, it be­came clear just how much mod­i­fi­ca­tion a pig — an an­i­mal cho­sen be­cause it was both close to hu­mans and easy to mass pro­duce — would re­quire, while the dis­cov­ery of a porcine virus vague­ly rem­i­nis­cent of HIV alarmed pub­lic health au­thor­i­ties deal­ing with the dead­liest days of the AIDS cri­sis.

Since then, a hand­ful of com­pa­nies have in­tro­duced a slew of new mod­i­fi­ca­tions and strate­gies and test­ed the re­sult­ing or­gans in non-hu­man pri­mates, in some cas­es get­ting the mon­keys to sur­vive for years.

The field, stocked with big and com­pet­i­tive per­son­al­i­ties, be­gan to buzz about who would be the first to do it in hu­mans. The ques­tion is whether or not Mont­gomery’s pro­ce­dure ac­tu­al­ly helped to­ward the goal of do­ing it in a liv­ing pa­tient who will have to be able to sur­vive off the or­gan.

“Peo­ple are chas­ing — who will be first? ‘I want to be first!’ ‘I want to be first!'” said Kaz Ya­ma­da, di­rec­tor of sur­gi­cal re­search, Co­lum­bia Cen­ter for Trans­la­tion­al Im­munol­o­gy. But “our goal is to cure the pa­tient, not to say, ‘I’m first.'”

Mont­gomery’s pro­ce­dure arose out of dis­cus­sions be­tween the trans­plant team at NYU and the uni­ver­si­ty’s renowned bioethi­cist de­part­ment, led by Art Ca­plan, who proac­tive­ly out­lined how, in the right con­di­tions, a brain-dead pa­tient could be the best first test for a xeno­trans­plant. (They al­so ad­vised against grant­i­ng ex­clu­siv­i­ty to any news out­let, fear­ing the me­dia fren­zy that in­deed en­sued when NYU did so. “I don’t win all my fights,” Ca­plan told me.)

But the idea of us­ing the re­cent­ly de­ceased as a test case for xeno­trans­plan­ta­tion goes back to at least Thomas Star­zl, of­ten con­sid­ered the fa­ther of the field, who first pro­posed it in the ear­ly 2000s, said Uni­ver­si­ty of Mi­a­mi sur­geon Joe Tec­tor.

Joe Tec­tor

Long one of the field’s most promi­nent fig­ures, Tec­tor had con­sid­ered do­ing it him­self. But by the 2010s, it no longer seemed nec­es­sary. Al­though Mont­gomery con­sult­ed with him pri­or to the op­er­a­tion, Tec­tor him­self had lost in­ter­est.

“We knew the bi­ol­o­gy,” he said. “We weren’t as com­fort­able that that would give us use­ful in­for­ma­tion.”

A lot had changed since the ear­ly 2000s, when Star­zl first pro­posed the idea.

Mont­gomery said his ex­per­i­ment showed that pa­tients wouldn’t in­stant­ly re­ject the mod­i­fied pig. But the lone ge­net­ic mod­i­fi­ca­tion Unit­ed gave the pig was first done suc­cess­ful­ly 20 years ago. And Ya­ma­da showed back in 2004 that the mod­i­fi­ca­tion — knock­ing out a sug­ar called al­pha-gal that all pri­mates, in­clud­ing hu­mans, have an­ti­bod­ies against — pre­vents pri­mates from in­stant­ly re­ject­ing the or­gans, al­low­ing them to live in that ex­per­i­ment for 83 days.

That find­ing has been held up re­peat­ed­ly, ex­perts say, with some mon­keys liv­ing for hun­dreds of days af­ter re­ceiv­ing or­gans from pigs mod­i­fied with that ed­it alone.

There’s dis­agree­ment with­in the xeno­trans­plan­ta­tion on how many ed­its will ul­ti­mate­ly be need­ed: Tec­tor’s pigs have three; eGe­n­e­sis, the well-backed Har­vard-spin­out, and Qi­han Biotech, its Chi­nese off­shoot that Holtz­man now chairs, have test­ed dozens; at Co­lum­bia, Ya­ma­da and Sykes use on­ly the one ed­it but al­so trans­plant a pig’s thy­mus, along­side the kid­ney, to try to get long-term T cell tol­er­ance.

The groups are now com­pet­ing to get the right FDA-ap­proved fa­cil­i­ties and sup­ply chains to make do­na­tions from a pig to a liv­ing pa­tient pos­si­ble, to show they can get con­sis­tent long-term sur­vival in mon­keys. All agreed that there were am­ple da­ta show­ing hu­mans wouldn’t re­ject a mod­i­fied pig or­gan in­stant­ly, or in the 54 hours Mont­go­mo­ery stud­ied.

For Tec­tor, it was “com­fort­ing,” he said, to now have val­i­da­tion in hu­mans, even if he wouldn’t have done it him­self. Oth­ers were less san­guine.

“I can’t imag­ine that things would be so much dif­fer­ent in hu­mans to think that this was re­al­ly in­for­ma­tive,” said Jim Mark­mann, chief of trans­plant at Mass­a­chu­setts Gen­er­al. (Mark­mann is al­so a sci­en­tif­ic ad­vi­sor for eGe­n­e­sis.) “I think it was more sen­sa­tion­al­ism.”

Unit­ed Ther­a­peu­tics, a com­pa­ny that has long court­ed both hype and se­cre­cy, did not re­spond to an in­ter­view re­quest or de­tailed ques­tions. At a press con­fer­ence Thurs­day, Mont­gomery said he used a pig that on­ly had the sin­gle ed­it be­cause al­pha-gal is the most im­por­tant knock­out for pre­vent­ing im­me­di­ate re­jec­tion and be­cause the FDA had al­ready cleared pigs with the ed­it for con­sump­tion and some re­search pur­pos­es.

He ar­gued that you could nev­er be sure the an­i­mal re­sults will trans­late in­to hu­mans un­til it’s ac­tu­al­ly done. And he said a full peer-re­viewed pub­li­ca­tion out­lin­ing the pro­ce­dure and its re­sults was com­ing.

“There have been many oth­er ex­am­ples of pre­clin­i­cal pri­mate stud­ies that have not trans­lat­ed well in­to what hap­pens in hu­mans,” he said. “We do have quite a bit of non­hu­man pri­mate da­ta but whether we’re go­ing to see the same things when we go to hu­man tri­als is re­al­ly not some­thing that we can re­ly up­on.”

Still, there was at least one point he and many of the out­side ex­perts agreed up­on. Al­though Holtz­man feared that the hype around the op­er­a­tion could de­tract from “peo­ple with in­tegri­ty and sci­en­tif­ic chops … who are the best hope for mak­ing this stuff hap­pen,” Sykes and Mark­mann ar­gued that it could ac­tu­al­ly help xeno­trans­plan­ta­tion, even if it con­tributed noth­ing to the sci­ence.

Mak­ing pig-to-hu­man trans­plants a re­al­i­ty will re­quire not on­ly strong re­sults in mon­key stud­ies, but al­so the trust of reg­u­la­tors and the pub­lic.

That has not al­ways been easy to win, but know­ing that noth­ing cat­a­stroph­ic hap­pened for at least the first 54 hours might help. Sykes, asked if she would have done the ex­per­i­ment, said that might be not be the right ques­tion.

“I’m hap­py to reap the ben­e­fits of it hav­ing been done,” Sykes said. “Of peo­ple hav­ing as­sur­ance that some­thing bad is not go­ing to hap­pen. I think that’s help­ful.”

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Adam Russell, ARPA-H's incoming acting deputy director

NI­H's new, in­de­pen­dent break­through drug ac­cel­er­a­tor ARPA-H gets its first em­ploy­ee

Despite the controversy of housing it in NIH, HHS Secretary Xavier Becerra on Wednesday afternoon formally announced the establishment of the Advanced Research Project Agency for Health (ARPA-H) as an independent entity within the NIH, as HHS had previously stipulated that “NIH may not subject ARPA-H to NIH policies.”

Becerra also announced the appointment of ARPA-H’s inaugural employee, Adam Russell, who will serve as acting deputy director.

Katrine Bosley (AP Photo/Mark Lennihan)

For­mer Ed­i­tas CEO Ka­trine Bosley goes the VC route, join­ing ear­ly-stage in­vestor

More than three years after abruptly exiting Editas Medicine, Katrine Bosley is leaping to the venture capital side of things.

London-based early-stage investor Advent Life Sciences announced Thursday that Bosley is joining the firm as venture partner. It’s also adding two general partners to the team: Dominic Schmidt, formerly of Syncona, will be in the UK; and Satish Jindal, most recently the CEO of investment fund BioMotiv, will be based in Boston, just like Bosley.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Serhat Gumrukçu, Enochian BioSciences co-founder (Seraph Research Institute)

LA biotech founder ar­rest­ed, charged in mur­der-for-hire scheme be­hind 2018 death

A biotech founder has been arrested and charged for his role in a murder-for-hire scheme that resulted in the death of a man in Vermont back in 2018.

Serhat Gumrukçu, the co-founder of Enochian BioSciences, was arrested in Los Angeles, where the company is based, according to the Department of Justice. He was charged alongside Berk Eratay of Las Vegas, and a third person, Jerry Banks of Colorado, was previously arrested for kidnapping and allegedly murdering the victim, Gregory Davis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

ProFound Therapeutics founding team

Flag­ship's lat­est biotech could turn some of the thou­sands of new pro­teins it dis­cov­ered in­to ther­a­pies — and it has $75M to start

Flagship Pioneering, the incubator of Moderna and dozens of other biotechs, says it has landed upon tens of thousands of previously undiscovered human proteins. The VC shop wants to potentially turn them into therapeutics.

Like other drug developers that have turned proteins into therapeutics (think insulin for diabetes), Flagship’s latest creation, ProFound Therapeutics, wants to tap into this new trove of proteins as part of its mission to treat indications ranging from rare diseases to cancer to immunological diseases.

Richard Silverman, Akava Therapeutics founder and Northwestern professor

This time around, Lyri­ca's in­ven­tor is de­vel­op­ing his North­west­ern dis­cov­er­ies at his own biotech

Richard Silverman was left in the dark for the last five years of clinical development of the drug he discovered. The Northwestern University professor found out about the first approval of Lyrica, in the last few days of 2004, like most other people: in the newspaper.

What became one of Pfizer’s top-selling meds, at $5 billion in 2017 global sales before losing patent protection in 2019, started slipping out of his hands when Northwestern licensed it out to Parke-Davis, one of two biotechs that showed interest in developing the drug in the pre-email days, when the university’s two-person tech transfer team had to ship out letters to garner industry appetite.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Michael Corbo, Pfizer CDO of inflammation & immunology

UP­DAT­ED: Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

Pfizer has laid out the detailed results behind its boast that etrasimod — the S1P receptor modulator at the center of its $6.7 billion buyout of Arena Pharma — is the winner of the class, potentially leapfrogging an earlier entrant from Bristol Myers Squibb.

Pivotal data from the ELEVATE program in ulcerative colitis — which consists of two Phase III trials, one lasting 52 weeks and the other just 12 weeks — illustrate an “encouraging balance of efficacy and safety,” according to Michael Corbo, chief development officer of inflammation & immunology at Pfizer. The company is presenting the results as a late breaker at Digestive Disease Week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly set to in­vest $2.1B in home state man­u­fac­tur­ing boost

Eli Lilly is looking to expand its footprint in its home Hoosier State by making a major investment in manufacturing.

The pharma is investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County, northwest of Lilly’s headquarters in Indianapolis.

The two new facilities will expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Up­dat­ed: US sees spike in Paxlovid us­age as Mer­ck­'s mol­nupi­ravir and As­traZeneca's Evusheld are slow­er off the shelf

New data from HHS show that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the US market, averaging about 33,000 courses administered per week in that time.